Pomalyst — Competitive Intelligence Brief

Pomalyst (pomalidomide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thalidomide Analog [EPC]. Area: Oncology.

marketed Thalidomide Analog [EPC] Protein cereblon Oncology

Target snapshot

Pomalyst (pomalidomide) — Bristol-Myers Squibb. Pomalyst works by binding to the cereblon protein, which disrupts the function of certain genes involved in cancer cell growth.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pomalyst TARGET	pomalidomide	Bristol-Myers Squibb	marketed	Thalidomide Analog [EPC]	Protein cereblon	2013-01-01
Viekira Pak (Copackaged)	DASABUVIR	AbbVie	marketed	Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor	Protein cereblon	2014-01-01
Lenali	Lenali	Singapore General Hospital	marketed		Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor
POMA	POMA	Bristol	marketed		Protein cereblon, Cereblon isoform 4
Revlimid	Revlimid	M.D. Anderson Cancer Center	marketed		Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor
Thalomid	Thalomid	Ann & Robert H Lurie Children's Hospital of Chicago	marketed		Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Protein cereblon
POMALIDOMIDE	POMALIDOMIDE		marketed	Thalidomide Analog [EPC]		2013-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2028-09-17 — Viekira Pak (Copackaged) · 8501238 · US
• 2028-11-09 — Viekira Pak (Copackaged) · 9139536 · US
• 2029-05-17 — Viekira Pak (Copackaged) · 8188104 · US
• 2029-09-10 — Viekira Pak (Copackaged) · 8642538 · US
• 2030-06-10 — Viekira Pak (Copackaged) · 9006387 · US
• 2031-04-10 — Viekira Pak (Copackaged) · 8420596 · US
• 2031-04-10 — Viekira Pak (Copackaged) · 9044480 · US
• 2031-06-09 — Viekira Pak (Copackaged) · 8686026 · US
• 2032-04-13 — Viekira Pak (Copackaged) · 8691938 · US
• 2032-05-17 — Viekira Pak (Copackaged) · 10201541 · US
• 2032-05-17 — Viekira Pak (Copackaged) · 10201584 · US
• 2032-09-04 — Viekira Pak (Copackaged) · 8492386 · US
• 2032-09-04 — Viekira Pak (Copackaged) · 8680106 · US
• 2032-09-04 — Viekira Pak (Copackaged) · 8685984 · US
• 2032-09-04 — Viekira Pak (Copackaged) · 8466159 · US
• 2033-10-18 — Viekira Pak (Copackaged) · 10201542 · US
• 2033-10-18 — Viekira Pak (Copackaged) · 9629841 · US
• 2035-01-02 — Viekira Pak (Copackaged) · 9744170 · US
• 2035-01-02 — Viekira Pak (Copackaged) · 10105365 · US
• 2035-01-02 — Viekira Pak (Copackaged) · 9333204 · US

Sponsor landscape (Thalidomide Analog [EPC] class)

1. · 2 drugs in this class
2. Bristol-Myers Squibb · 1 drug in this class